Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2020-05-21 Director's Dealing
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-05-21 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 20, 2020, reporting an amendment to the company's Severance and Change in Control Plan. The key content is about changes to executive severance arrangements and definitions related to Change in Control. There is no financial data or comprehensive financial report included. The document is primarily an announcement of a management-related change, specifically concerning compensatory arrangements and governance matters related to executives. According to the filing definitions, announcements about changes in senior management or board-related matters fall under Board/Management Information (MANG). The document is not an earnings release, annual report, or any other financial report type. Therefore, the appropriate classification is MANG with high confidence.
2020-05-20 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC by Organovo Holdings, Inc. It reports the termination of a material definitive agreement (a merger agreement) and provides detailed voting results from a special meeting of stockholders related to the merger proposals. The document includes information about the adjournment and reconvening of the special meeting, the voting outcomes on specific proposals, and a press release attached as an exhibit. The content focuses on corporate events, voting results, and termination of a merger agreement rather than financial results, management discussion, or audit information. The presence of detailed voting results and the submission of matters to a vote of security holders clearly aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6930 characters) and detailed voting data support this classification rather than a brief announcement or a full report. Therefore, the appropriate classification is DVA with high confidence.
2020-04-08 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content includes the termination of a material definitive agreement (a merger agreement), detailed voting results from a special meeting of stockholders, and a press release about the termination and voting results. The document does not contain full financial statements or comprehensive financial analysis, but rather reports on corporate events and shareholder voting outcomes. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Merger & Acquisition filings (MA) or Declaration of Voting Results (DVA) because it includes multiple types of information and is a current report form. The document length (6757 characters) and detailed event description support this classification with high confidence.
2020-04-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an "Other Events" item about the adjournment of a Special Meeting and includes a press release as an exhibit. The document is short (3294 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed disclosures typical of Annual Reports, Earnings Releases, or Interim Reports. It also does not fit into categories like Board/Management changes, M&A, or Capital updates. Given the nature and length, this filing best fits the Regulatory Filings (RNS) category, which is a fallback for miscellaneous SEC filings that do not fit other categories.
2020-04-01 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-6(b) under the Securities Exchange Act of 1934, which are rules related to merger communications and proxy solicitations. The content is an email and letter correspondence from Organovo Holdings, Inc. to institutional stockholders discussing the proposed merger with Tarveda Therapeutics, Inc. It references the definitive proxy statement/prospectus/information statement filed earlier and urges stockholders to support the merger. The document is a communication related to the solicitation of proxies for a merger vote, containing detailed arguments supporting the merger and requesting engagement with stockholders. It is not the proxy statement itself, nor a formal merger filing like a DEFM14A or SC TO-*, but a Rule 425 communication which is a type of merger-related solicitation material. This type of document is best classified under Merger & Acquisition (MA) filings, which include merger communications such as Form 425 filings. The document is substantive and lengthy (over 14,000 characters), containing detailed merger-related information and solicitation content, not just an announcement or brief notice. Therefore, the appropriate classification is MA with high confidence.
2020-04-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.